Zoe Bollinger
Sep 4, 2015
Hayman Capital’s Kyle Bass Vows to Continue Drug-Patent Challenges
Hedge-fund manager Kyle Bass says he’ll persist in his campaign to invalidate what he calls weak pharmaceutical patents, despite being handed two early setbacks in recent weeks.